Zhang, S., Anjum, R., Squillace, R., Nadworny, S., Zhou, T., Keats, J., … Rivera, V. M. (2016). The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clinical Cancer Research, 22(22), 5527–5538. doi:10.1158/1078-0432.ccr-16-0569
